Cyxone AB Logo

Cyxone AB

A clinical-stage biotech developing therapies for autoimmune and autoinflammatory diseases.

CYXO | ST

Overview

Corporate Details

ISIN(s):
SE0007815428 (+2 more)
LEI:
54930034OH16ROAY4K87
Country:
Sweden
Address:
Hyllie Boulevard 34, 215 32 Malmö

Description

Cyxone AB is a clinical-stage biotechnology company focused on developing disease-modifying therapies for autoimmune and autoinflammatory diseases. The company's portfolio includes two primary drug candidates in clinical development. Rabeximod is an immunomodulating agent being investigated for the treatment of rheumatoid arthritis. T20K is a drug candidate for multiple sclerosis, developed using the company's cyclotide technology platform, which is based on stable, plant-derived peptides. Cyxone aims to develop therapies that can significantly improve the quality of life for patients with these chronic conditions.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
No filings match the current criteria.

Automate Your Workflow. Get a real-time feed of all Cyxone AB filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Cyxone AB

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Cyxone AB via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2023-06-28 Carl Magnus Högerkorp Other Buy 64,950 40,788.60 SEK
2023-06-27 Carl Magnus Högerkorp Other Buy 6,050 3,690.50 SEK
2023-03-03 Carl Magnus Högerkorp Other Buy 100,010 51,005.10 SEK
2023-03-02 Carl Magnus Högerkorp Other Buy 10,873 5,653.96 SEK
2021-07-15 Bert Junno Other Other 1,788,732 7,763,096.88 SEK
2021-07-15 Bert Junno Other Other 1,788,732 N/A
2021-07-14 Bert Junno Other Other 1,788,786 7,790,163.03 SEK
2021-07-14 Bert Junno Other Other 1,788,786 N/A
2021-07-12 Mikeoo Holding AB Other Other 1,788,732 7,441,125.12 SEK
2021-07-12 Mikael Lindstam Other Other 1,788,732 N/A

Peer Companies

1NKEMIA Logo
Biotechnology company providing R&D and services for the life sciences sector.
Spain
IKM
2cureX AB Logo
Develops an IVD test using 3D tumoroids to predict patient response to cancer drugs.
Sweden
2CUREX
Abera Bioscience AB Logo
Develops mucosal vaccines using a proprietary Outer Membrane Vesicle (OMV) platform.
Sweden
ABERA
Clinical-stage biopharma developing therapeutics for oncology and viral diseases.
South Korea
203400
ABL Bio Inc. Logo
Develops bispecific antibody therapeutics for oncology and neurodegenerative diseases.
South Korea
298380
Abpro Holdings, Inc. Logo
Clinical-stage biotech developing antibody therapeutics for oncology and ophthalmology.
United States of America
ABP
Absci Corp Logo
A generative AI drug creation company developing biologic medicines.
United States of America
ABSI
Achiko AG Logo
A digital services platform for cross-border business compliance and engagement.
Switzerland
ACHI
Active Biotech Logo
Biotechnology company developing drugs for oncology and inflammatory eye disorders.
Sweden
ACTI
Adagene Inc. Logo
Clinical-stage biotech developing antibody-based immunotherapies for oncology.
United States of America
ADAG

Report Sent!

Thank you. We will check the data and update it shortly.

Talk to a Data Expert

Have a question? We'll get back to you promptly.